The US Food and Drug Administration (FDA) said it has recommended five pharmaceutical firms to voluntarily recall their diabetes drug metformin after the agency found high levels of a possible cancer-causing impurity in some versions of the medication.
The agency said the drugs contained the probable carcinogen N-nitrosodimethylamine (NDMA) beyond acceptable limits in their extended-release formulations alone.
NDMA contamination was responsible for the recall of heartburn drug Zantac sold by Sanofi SA and some generic versions of the treatment last year.
However, the agency said patients should continue taking metformin tablets even after recalls occur until they consult with their health care professional who can prescribe a replacement.
No comments:
Post a Comment